Why Patients Can't Get Off PPIs

When a patient stops a proton pump inhibitor and the reflux comes back worse than before, that is not proof they needed the drug. It is a predictable physiological rebound, it has a timeline, and it is the reason most attempts to stop fail in the first fortnight.

Rebound acid hypersecretion

The drug does not just suppress acid. It changes the machinery that makes it.

Acid secretion is regulated by gastrin, and gastrin release is held in check by the acid itself — a negative feedback loop. Suppress acid for months and that brake comes off. Gastrin rises and stays risen. Chronically elevated gastrin is trophic to the enterochromaffin-like cells and, over time, to parietal cell mass.

So the patient on long-term omeprazole is not simply a patient with less acid. They are a patient with more acid-producing capacity than they started with, held in check by a daily tablet.

Take the tablet away and that capacity is suddenly unopposed. Acid output overshoots — not back to baseline, past it. Symptoms return worse than they were before the drug was ever prescribed.

The patient concludes they need it. The prescriber, reasonably, agrees. And the loop closes for another five years.

The overshoot is temporary. It is generally described as lasting somewhere between two and four weeks, which is considerably longer than most people will tolerate severe reflux without going back to something that works. That mismatch — between how long the rebound lasts and how long a patient will white-knuckle it — is the actual clinical problem.

It happens to people who never had reflux

This is the part that settles the argument, and it is worth knowing well enough to explain to a patient.

The question was put directly: if you give proton pump inhibitors to healthy volunteers with no reflux symptoms at all, and then withdraw the drug, do they develop acid-related symptoms? Placebo-controlled withdrawal studies found that a meaningful proportion did — heartburn, acid regurgitation, dyspepsia — in people who had none of it before the drug.

They did not have reflux. They were given a drug for it, and stopping the drug gave them the condition.

That finding does two things. It establishes that rebound is a drug effect rather than relapse of an underlying problem. And it gives you something concrete to say to a patient who is convinced their symptoms prove they need the medication — because the most useful thing you can offer in week two is not a supplement, it is the knowledge that this was expected and it ends.

The review that never happened

Ask a patient on long-term acid suppression why they take it and you will often get a shrug, or a story about something that happened in 2014.

PPIs are frequently started appropriately — for a defined problem, for a defined course. What is missing is the end of the course. The prescription renews, nobody revisits it, and a four-week intervention becomes an eleven-year one.

So before any discussion of stopping, establish three things:

• What was it started for? An ulcer, H. pylori eradication, NSAID protection, oesophagitis, or undifferentiated reflux.

• Does that reason still apply? Often it plainly does not — the NSAID stopped years ago, the ulcer healed, the infection was treated.

• Has anyone looked since? If the original problem was never actually investigated, you are dealing with symptoms attributed to acid rather than a documented acid problem, and those are not the same thing.

That third one matters more than it sounds. Plenty of patients were given a PPI as an empirical trial, it partially worked, and the trial quietly became a diagnosis.

What suppression costs

Acid is not a design flaw. It does several jobs, and removing it for years has downstream consequences that show up in the labs you are already running.

B12. Dietary B12 arrives bound to protein and requires acid and pepsin to be released before intrinsic factor can do anything with it. Suppress acid long enough and absorption falls — and because serum B12 lags tissue status, MMA is the marker that will show you first.

Minerals. Iron, magnesium and calcium absorption all depend on an acidic environment to some degree. Unexplained low ferritin or refractory low magnesium in a patient on long-term PPIs is worth connecting rather than supplementing around.

The barrier. Gastric acid is a gate. It kills a meaningful proportion of what arrives in food, and lowering it raises the odds of enteric infection and of bacterial overgrowth further down.

Protein digestion. Pepsin needs acid to work. Reduced acid means reduced protein breakdown, which has its own consequences for everything downstream.

None of this makes PPIs bad drugs. They are excellent drugs, used for years in people whose original indication expired.

The loop

Here is the part that reframes the whole case, and it is why this is a gut post rather than a pharmacology one.

Acid is one of the things keeping the small intestine relatively sterile. Lower it for long enough and you raise the odds of bacterial overgrowth upstream. Overgrowth produces gas. Gas raises intra-abdominal pressure. Raised pressure pushes stomach contents the wrong way through the lower oesophageal sphincter.

The patient gets reflux — and the reflux is now being driven by too little acid rather than too much.

They report it. The dose goes up. Acid falls further. Overgrowth worsens. More gas, more pressure, more reflux.

This is why some patients escalate for years and never settle, and why the question what if this is low acid rather than high is worth asking of anyone who has been climbing the dose without ever getting comfortable. It is also why clearing an overgrowth sometimes resolves reflux that a decade of acid suppression could not.

It is not the explanation for every case. Plenty of reflux is straightforwardly reflux. But it is the explanation that never gets considered, because the drug that causes it is the drug being used to treat it.

Who should not come off

Deprescribing is not the goal for everyone, and this is the paragraph to be unambiguous about.

Some patients are on acid suppression for a reason that has not gone anywhere:

• Barrett's oesophagus

• Severe or erosive oesophagitis

• Zollinger-Ellison syndrome and other hypersecretory states

• Ongoing NSAID or antiplatelet use where the PPI is gastroprotective, particularly with prior bleeding

• A history of GI bleed

For these patients the drug is doing a job and stopping it carries real risk. That decision belongs with the prescribing physician, not with you, and the useful contribution is to support the patient's nutrient status and digestion while they remain on it rather than to campaign for its removal.

More generally: a PPI someone else prescribed is someone else's decision to change. Work with the prescriber. A practitioner who talks a patient off a medication behind their physician's back has created a problem no clinical result will fix.

A taper that holds

The principles are consistent even though the specifics belong to the individual patient.

Step down, do not stop. Abrupt cessation produces the full overshoot at once. Reducing gradually — lower dose, then less frequent dosing, often with a step onto a weaker agent before stopping altogether — lets the gastrin signal settle without the cliff.

Tell the patient what is coming. This is the highest-value thing you will do. A patient who knows a flare is expected, has a rough timeline, and understands it is the drug rather than their disease will hold through week two. A patient who was not told will be back on 40mg by Thursday and will believe the attempt proved something.

Have something for the window. They need a plan for the symptomatic period, or willpower is the only tool and willpower loses.

Go slower with longer use. Someone on PPIs for a decade needs a longer runway than someone on them for a year.

Work on why the reflux existed. Motility, weight, meal timing, alcohol, the overgrowth loop above. Taper without addressing the driver and you are simply removing the suppression from an unaddressed problem.

Expect it to take months. Patients who have been on these drugs for years do not come off in three weeks, and treating a slow taper as failure is how people end up back where they started.

The GHT Academy Gut Guide has the PPI wean-off protocol in full — the step-down structure, what to use through the rebound window with specific dosing and timelines, stomach acid testing, and the 5R framework around it. It is the reference I built for my own team.